These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

302 related articles for article (PubMed ID: 11396219)

  • 1. A pilot study of AFL-T (doxorubicin, 5-fluorouracil, leucovorin, and tamoxifen) combination chemotherapy for hormone-refractory prostate cancer.
    Lin CC; Hsu CH; Chen J; Tsai TC; Cheng AL; Pu YS
    Anticancer Res; 2001; 21(2B):1385-90. PubMed ID: 11396219
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and efficacy of the MDR inhibitor Incel (biricodar, VX-710) in combination with mitoxantrone and prednisone in hormone-refractory prostate cancer.
    Rago RP; Einstein A; Lush R; Beer TM; Ko YJ; Henner WD; Bubley G; Merica EA; Garg V; Ette E; Harding MW; Dalton WS
    Cancer Chemother Pharmacol; 2003 Apr; 51(4):297-305. PubMed ID: 12721757
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ixabepilone (epothilone B analogue BMS-247550) is active in chemotherapy-naive patients with hormone-refractory prostate cancer: a Southwest Oncology Group trial S0111.
    Hussain M; Tangen CM; Lara PN; Vaishampayan UN; Petrylak DP; Colevas AD; Sakr WA; Crawford ED;
    J Clin Oncol; 2005 Dec; 23(34):8724-9. PubMed ID: 16314632
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biochemical modulation of doxorubicin by high-dose tamoxifen in the treatment of advanced hepatocellular carcinoma.
    Cheng AL; Yeh KH; Fine RL; Chuang SE; Yang CH; Wang LH; Chen DS
    Hepatogastroenterology; 1998; 45(24):1955-60. PubMed ID: 9951847
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Weekly paclitaxel and high-dose 5-fluorouracil plus leucovorin in hormone-refractory prostate cancer: in vitro combined effects and a phase II trial.
    Lin CC; Hsu CH; Hour TC; Cheng AL; Huang CY; Huang KH; Chen J; Pu YS
    Urol Oncol; 2007; 25(3):207-13. PubMed ID: 17483017
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oral estramustine and cyclophosphamide in patients with metastatic hormone refractory prostate carcinoma: a phase II study.
    Bracarda S; Tonato M; Rosi P; De Angelis V; Mearini E; Cesaroni S; Fornetti P; Porena M
    Cancer; 2000 Mar; 88(6):1438-44. PubMed ID: 10717628
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A phase II study of weekly methotrexate, cisplatin, and 24-hour infusion of high-dose 5-fluorouracil and leucovorin (MP-HDFL) in patients with metastatic and recurrent esophageal cancer-improving toxicity profile by infusional schedule and double biochemical modulation of 5-fluorouracil.
    Hsu CH; Cheng AL; Hsu C; Yang CH; Lu YS; Lin CC; Bu CF; Yeh KH
    Anticancer Res; 2002; 22(6B):3621-7. PubMed ID: 12552966
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A phase II study of irinotecan with bi-weekly, low-dose leucovorin and bolus and continuous infusion 5-fluorouracil (modified FOLFIRI) as salvage therapy for patients with advanced or metastatic gastric cancer.
    Kim SG; Oh SY; Kwon HC; Lee S; Kim JH; Kim SH; Kim HJ
    Jpn J Clin Oncol; 2007 Oct; 37(10):744-9. PubMed ID: 17923456
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase II trial of oral uracil/tegafur plus leucovorin in patients with hormone-refractory prostate carcinoma.
    Bhandari MS; Pienta KJ; Fardig J; Olson K; Smith DC
    Cancer; 2006 Apr; 106(8):1715-21. PubMed ID: 16534795
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Paclitaxel and leucovorin-modulated infusional 5-fluorouracil combination chemotherapy for metastatic gastric cancer.
    Cho BC; Kim JH; Kim CB; Sohn JH; Choi HJ; Lee YC; Ahn JB
    Oncol Rep; 2006 Mar; 15(3):621-7. PubMed ID: 16465422
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase II trial of paclitaxel, estramustine, etoposide, and carboplatin in the treatment of patients with hormone-refractory prostate carcinoma.
    Smith DC; Chay CH; Dunn RL; Fardig J; Esper P; Olson K; Pienta KJ
    Cancer; 2003 Jul; 98(2):269-76. PubMed ID: 12872344
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase I-II trial evaluating combined intensity-modulated radiotherapy and in situ gene therapy with or without hormonal therapy in treatment of prostate cancer-interim report on PSA response and biopsy data.
    Teh BS; Ayala G; Aguilar L; Mai WY; Timme TL; Vlachaki MT; Miles B; Kadmon D; Wheeler T; Caillouet J; Davis M; Carpenter LS; Lu HH; Chiu JK; Woo SY; Thompson T; Aguilar-Cordova E; Butler EB
    Int J Radiat Oncol Biol Phys; 2004 Apr; 58(5):1520-9. PubMed ID: 15050332
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vinorelbine, doxorubicin, and prednisone in androgen-independent prostate cancer.
    Borden LS; Clark PE; Lovato J; Hall MC; Stindt D; Harmon M; M Mohler R; Torti FM
    Cancer; 2006 Sep; 107(5):1093-100. PubMed ID: 16888761
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 5-Fluorouracil versus folinic acid and 5-fluorouracil in advanced, hormone-resistant prostate cancer: a prospective randomized pilot trial.
    Breul J; Jakse G; Forster G; Lampel A; Rohani A; Hartung R
    Eur Urol; 1997; 32(3):280-3. PubMed ID: 9358213
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Phase I/II study of weekly paclitaxel and 3 days of high dose oral estramustine in patients with hormone-refractory prostate carcinoma.
    Ferrari AC; Chachoua A; Singh H; Rosenthal M; Taneja S; Bednar M; Mandeli J; Muggia F
    Cancer; 2001 Jun; 91(11):2039-45. PubMed ID: 11391583
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase II trial of Oxaliplatin and 5-Fluorouracil/Leucovorin combination in epithelial ovarian carcinoma relapsing within 2 years of platinum-based therapy.
    Sundar S; Symonds RP; Decatris MP; Kumar DM; Osman A; Vasanthan S; O'byrne KJ
    Gynecol Oncol; 2004 Aug; 94(2):502-8. PubMed ID: 15297195
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diethylstilbestrol and docetaxel: a Phase II study of tubulin active agents in patients with metastatic, androgen-independent prostate cancer.
    Montgomery RB; Nelson PS; Lin D; Ryan CW; Garzotto M; Beer TM
    Cancer; 2007 Sep; 110(5):996-1002. PubMed ID: 17639587
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of an irinotecan plus bolus 5-fluorouracil and L-leucovorin regimen for metastatic colorectal cancer in Japanese patients: experience in a single institution in Japan.
    Yoshino T; Boku N; Onozawa Y; Hironaka S; Fukutomi A; Yamaguchi Y; Hasuike N; Yamazaki K; Machida N; Ono H
    Jpn J Clin Oncol; 2007 Sep; 37(9):686-91. PubMed ID: 17720736
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prednisone monotherapy in asymptomatic hormone refractory prostate cancer.
    Heng DY; Chi KN
    Can J Urol; 2006 Dec; 13(6):3335-9. PubMed ID: 17187697
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase II study of the paclitaxel, cisplatin, 5-fluorouracil and leucovorin (TPFL) regimen in the treatment of advanced or metastatic gastric cancer.
    Jung JY; Kwon JH; Kim JH; Song HH; Kim I; Lee KS; Kim HJ; Zang DY; Ahn JS; Lee JA; Park YI
    Oncol Rep; 2009 Feb; 21(2):523-9. PubMed ID: 19148531
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.